medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2012, Number 3

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2012; 10 (3)

Biologic agents and the treatment of psoriasis

Villarreal MA, Gómez FM, Ocampo CJ

Language: Spanish
References: 25
Page: 198-204
PDF size: 203.89 Kb.


ABSTRACT

Psoriasis is considered as a genetic, immunologic, inflammatory and chronic disease. It is characterized by the presence of erythematous, scaly plaques. It affects approximately 2% of the population. There are different therapeutic approaches and it is recommended to start with drugs that produce less side effects. The understanding of the immunologic basis of the disease has enabled the design of novel therapeutic agents. The new biologic agents provide selective therapeutic modalities that can minimize side effects. These agents are proteins that can be extracted from animal tissue or produced by recombinant DNA technology and possess pharmacologic activity. They bind to specific antigens or cytokines preventing or reducing psoriasis manifestations. There are 3 different classes of biologic agents: monoclonal antibodies, fusion proteins and recombinant cytokines. Five of these agents are currently approved by the FDA for their use in psoriasis: alefacept, etanercept, infliximab, adalimumab and ustekinumab. Clinical trials to study the security and efficacy of other agents such as secukinumab and briakinumab are being carried out.
In this article we review the mechanisms of action, indications, contraindications, doses and efficacy of every biologic agent used in the treatment of moderate to severe psoriasis.


REFERENCES

  1. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB et al. “Guidelines of care for the management of psoriasis and psoriatic arthritis Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics”. J Am Acad Dermatol. 2008; 58: 826-850.

  2. Arenas, R. “Psoriasis”. En: Dermatología. Atlas, diagnóstico y tratamiento. Cap. 121, México, McGraw-Hill Interamericana, 2009: 594.

  3. Griffiths C, Christophers E, Barker J, Chalmers R, Chimenti S, Krueger G et al. “A classification of psoriasis vulgaris according to phenotype”. British Journal of Dermatology. 2007; 156: 258-262.

  4. Krueger JG. “The immunologic basis for the treatment of psoriasis with new biologic agents”. J Am Acad Dermatol. 2002; 46: 1-23.

  5. Nestle FO, Kaplan DH, Barker J. “Psoriasis”. N Engl J Med. 2009; 361: 496-509.

  6. Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR. “New treatments for psoriasis: Which biologic is best?”. J Dermatolog Treat. 2006; 17: 96-107.

  7. Lee MR, Cooper AJ. “Biologic agents in psoriasis”. Australasian Journal of Dermatology. 2006; 47: 217-230.

  8. Amaya Guerra M, Barba F, Blancas González F, Gómez Flores M, Gómez Trigo A, González Soto R y cols. “Consenso Mexicano para el Manejo de Terapia Biológica en Psoriasis”. Rev Cent Dermatol Pascua. Vol. 3, núm. 13, sep-dic, 2004.

  9. FDA Statement on the Voluntary Withdrawal of Raptiva From the U. S. Market. U. S Food and Drug Administration. Abril 8, 2009.

  10. Krueger G, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y et al. “A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis”. N Engl J Med. 2007; 356: 580-592.

  11. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C. “Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)”. The Lancet. Vol. 371, Issue 9625, pp. 1665-1674, 17 de mayo, 2008.

  12. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N et al. “Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)”. The Lancet. Vol. 371, núm. 9625, pp. 1675-1684, 17 de mayo, 2008.

  13. Chien A, Elder JT, Ellis CN. “Ustekinumab. A new option in psoriasis therapy”. Drugs. 2009; 69(9): 1141-1152.

  14. Griffiths C, Strober BE, Van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N et al. “Comparison of ustekinumab and etanercept for moderate- to-severe psoriasis”. N Engl J Med. 2010; 362: 118-128.

  15. Signorovitch J, Kantor E, Mulani P, Bao Y. “Comparison of response rates and drug costs during maintenance therapy with adalimumab versus ustekinumab in patients with moderate to severe psoriasis”. J Am Acad Dermatol. Vol. 62, núm. 3, marzo, 2010; Suppl 1, AB125.

  16. Kimball A, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J. “Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis”. Arch Dermatol. 2008; 144(2): 200-207.

  17. Kimball A, Zhong J, Valdes J, Gordon K. “Retreatment efficacy and long-term safety of the fully human, interleukin-12/-23 monoclonal antibody ABT-874 in the treatment of moderate to severe psoriasis: 48-week results from a phase II trial”. J Am Acad Dermatol. Vol. 60, núm. 3, 2009; Suppl 1, AB168.

  18. Gordon K, Langley R, Gottlieb A et al. “Efficacy and safety results from a phase III, randomized controlled trial comparing two dosing regimens of ABT-874 to placebo in patients with moderate to severe psoriasis”. J Eur Acad Derm Venereol. 2010; 24 Suppl 4: 1-83.

  19. Menter A, Gottlieb A, Leonardi C et al. “Efficacy and safety results of ABT-874 vs etanercept and placebo in patients with moderate to severe chronic plaque psoriasis”. J Eur Acad Derm Venereol. 2010; 24 Suppl 4: 1-83.

  20. Strober B, Crowley J, Yamauchi P et al. “ABT-874 versus etanercept and placebo in patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results”. J Eur Acad Derm Venereol. 2010; 24 Suppl 4: 1-83.

  21. Strober BE, Crowley JJ, Yamauchi PS, Olds M, Williams DA. “Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis”. British Journal of Dermatology. 2011; 165: 661-668.

  22. Kurzeja M, Rudnicka L, Olszewska M. “New interleukin-23 pathway inhibitors in dermatology: Ustekinumab, briakinumab, and secukinumab”. Am J Clin Dermatol. 2011; 12(2): 113-125.

  23. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G et al. “Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis”. Sci Transl Med. 6 de octubre, 2010; 2: 52ra72.

  24. Ferrándiz C. Carrascosa J. Boada A. “A new era in the management of psoriasis? The biologics: Facts and controversies”. Clin Dermatol. 1 de enero, 2010; 28(1): 81-87.

  25. Espinoza N, Herz M, Ocampo J, González R. “Nueva y prometedora opción en psoriasis: la terapia biológica”. Rev Med Inst Mex Seguro Soc. 2008; 46(4): 405-414.




2020     |     www.medigraphic.com